Exact Sciences To Present Late-Breaking Data From ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test At AACR Annual Meeting 2024
Portfolio Pulse from Benzinga Newsdesk
Exact Sciences Corp. (NASDAQ:EXAS) will present data from the ASCEND-2 study at the AACR Annual Meeting 2024, showcasing the effectiveness of its investigational multi-cancer early detection (MCED) blood test. The study, involving over 11,000 participants, demonstrates high detection rates and specificity for aggressive cancers and those without standard screening tests. Additionally, outcomes from the DETECT-A study will be presented, highlighting the potential of MCED tests in revolutionizing cancer screening.
April 08, 2024 | 4:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Exact Sciences Corp. is set to present significant data from the ASCEND-2 study, validating the effectiveness of its MCED blood test for early cancer detection. This includes high detection rates for aggressive cancers and those lacking standard screening tests.
The presentation of positive data from the ASCEND-2 study at a prestigious conference like AACR significantly boosts the credibility and potential market acceptance of Exact Sciences' MCED test. High detection rates and specificity, especially for aggressive cancers, underscore the test's potential to fill a critical gap in cancer screening. This could lead to increased interest from the medical community and investors, potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100